Brain cancer drug trial halted after just two patients

NCT ID NCT03149575

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This study tested a new drug called VAL-083 in people with glioblastoma, an aggressive brain cancer, that had come back after standard treatments. The goal was to see if VAL-083 could help patients live longer. However, the trial was stopped early after only 2 people enrolled, so no conclusions can be drawn about the drug's effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atlantic Neuroscience Institute - Brain Tumor Center of NJ

    Summit, New Jersey, 07901, United States

  • Dent Neurosciences Research Center

    Amherst, New York, 14226, United States

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California, 90027, United States

  • Mayo Clinic Cancer Center

    Rochester, Minnesota, 55905, United States

  • University of California, San Francisco - Division of Neuro-Oncology

    San Francisco, California, 94143, United States

Conditions

Explore the condition pages connected to this study.